Casgevy received FDA approval in December 2023 as the first CRISPR-based therapy authorized in the United States, initially for sickle cell disease and subsequently expanded to include transfusion-dependent beta-thalassemia. The approval carried enormous symbolic weight — the first therapeutic application of a technology that had captured public and scientific imagination for over a decade, deployed against a disease that had disproportionately affected patients of African descent for generations without meaningful pharmaceutical intervention beyond hydroxyurea and symptom management.

Two and a half years later, real-world experience with Casgevy provides the first substantial data on what CRISPR-based therapy actually means in clinical practice. The picture is more complex than either the initial excitement or subsequent critique captured.

How Casgevy Actually Works

Sickle cell disease results from a specific mutation in the beta-globin gene that produces abnormal hemoglobin. Under low-oxygen conditions, this abnormal hemoglobin polymerizes, causing red blood cells to deform into the characteristic sickle shape. Sickled cells cause the vaso-occlusive crises that define sickle cell disease morbidity.

Casgevy addresses this through an indirect but elegant mechanism. Rather than correcting the sickle cell mutation itself, the treatment uses CRISPR-Cas9 to disrupt the BCL11A gene in patient hematopoietic stem cells. BCL11A normally suppresses fetal hemoglobin production after birth. By disrupting BCL11A, Casgevy causes patient stem cells to reactivate fetal hemoglobin production. Fetal hemoglobin doesn't sickle under low-oxygen conditions and provides functional replacement for the defective adult hemoglobin.

The treatment process involves harvesting patient stem cells, shipping them to a manufacturing facility for CRISPR editing, myeloablative conditioning to eliminate existing bone marrow, and reinfusing edited cells that engraft and produce fetal hemoglobin-containing red cells for the patient's remaining lifetime.

The Clinical Efficacy Data

Efficacy data from the pivotal trials and post-approval real-world use has been meaningfully positive.

Vaso-occlusive crisis reduction — the primary clinical measure of sickle cell disease severity — has been dramatic. In pivotal trials, 90%+ of treated patients experienced elimination of severe crises. Real-world post-approval data has largely replicated this efficacy.

Fetal hemoglobin levels achieved by treatment average 40-50% of total hemoglobin, sufficient to prevent sickling in most physiological conditions. Levels have remained stable through follow-up to date (up to 4 years in some early trial patients).

Quality of life improvements have been substantial. Patients previously requiring multiple hospitalizations annually for pain crises typically require no crisis-related hospitalizations post-treatment. Chronic pain reduction has been meaningful. Return to normal activities including employment, education, and physical activity has improved for most treated patients.

Transfusion requirements have essentially eliminated for both sickle cell and beta-thalassemia patients whose disease previously required regular transfusion support.

These outcomes represent genuinely transformative benefit for individual patients who receive the treatment.

The Delivery Reality

Where the story becomes more complicated is in the delivery infrastructure required to actually treat patients.

Casgevy administration is not a simple pharmaceutical infusion. The complete treatment protocol involves:

The total treatment timeline runs 4-6 months from initial evaluation to hospital discharge, followed by years of ongoing monitoring. The intensity is comparable to bone marrow transplantation for cancer.

The complexity limits scaling substantially. Even if pricing were dramatically lower and insurance coverage universal, the specialized infrastructure required for treatment delivery represents a genuine bottleneck.

The Access Numbers Two Years In

As of mid-2026, fewer than 300 patients globally have received Casgevy treatment. This is substantially below early projections that anticipated 1,000+ treated patients in the first two years.

The gap between projected and actual utilization reflects several factors:

Pricing and coverage. The approximately $2.2 million list price has created ongoing insurance coverage battles. Even for insured patients, prior authorization requirements are complex and denials are common. Uninsured or underinsured patients face essentially insurmountable barriers.

Treatment center availability. The limited number of authorized centers creates geographic barriers. Patients often must travel substantial distances and remain near a center for months.

Treatment complexity. The 4-6 month treatment timeline requires life disruption that many patients cannot accommodate. Working patients face employment disruption; parents face childcare complications; patients without support systems struggle with the required medical management.

Patient hesitation. Some eligible patients have decided against treatment given uncertainty about long-term effects, fertility implications, and the intensive treatment process itself.

These factors combine to create effective access that is substantially narrower than the eligible population.

Casgevy represents the first practical evidence that CRISPR gene editing can deliver approved therapies to patients. It also represents the first practical evidence that regulatory approval and broad patient access are meaningfully different things.

The Long-Term Safety Question

Casgevy has been in patients too briefly to fully characterize long-term safety. Concerns that require ongoing monitoring include:

Cancer risk. CRISPR editing has known potential for off-target effects, and myeloablative conditioning itself has known cancer risks. Long-term cancer surveillance is ongoing for all treated patients.

Fertility and reproductive effects. The myeloablative conditioning causes infertility. Fertility preservation offering exists but adds complexity and cost.

Durability of edited cell engraftment. Current data supports durable engraftment through 4+ years but long-term (multi-decade) durability remains unknown.

Effects on other cell lineages. BCL11A affects genes beyond hemoglobin regulation. Long-term effects on immune function, cognitive development in pediatric patients, and other systems require ongoing monitoring.

None of these concerns has generated safety signals sufficient to change treatment recommendations, but the monitoring is real and appropriate.

The Alternative Comparison

Casgevy is not the only option for severe sickle cell disease. Alternative approaches include:

Hydroxyurea — established oral medication that reduces crisis frequency in many patients. Not curative but substantially cheaper and simpler than gene editing.

L-glutamine (Endari) — approved 2017, modest crisis frequency reduction. Complementary to hydroxyurea.

Crizanlizumab (Adakveo) — monoclonal antibody approved 2019, moderate crisis reduction.

Voxelotor (Oxbryta) — approved 2019, prevents hemoglobin polymerization. Withdrawn 2024 following safety concerns.

Allogeneic bone marrow transplantation — potentially curative but requires matched donor and carries substantial risks. Limited applicability.

Lyfgenia (Bluebird) — approved simultaneously with Casgevy, alternative gene therapy using lentiviral gene addition rather than CRISPR editing. Similar clinical outcomes, similar pricing, similar access constraints.

The alternative landscape is substantially more crowded than existed a decade ago. For patients who cannot access gene therapy for any reason, medical management options are more effective than they were previously.

What This Predicts for CRISPR More Broadly

The Casgevy experience provides some early evidence about what to expect as additional CRISPR-based therapies reach approval.

Efficacy for well-designed CRISPR therapies is likely to meet trial-based expectations. The technology works when properly deployed.

Access barriers due to pricing, complexity, and infrastructure requirements are likely to be substantial for most gene therapies at least through the 2020s. Broad patient access will require both cost reduction and delivery simplification.

Long-term safety monitoring will be essential and will occasionally identify concerns that shift clinical practice.

The gap between approved treatment and delivered treatment will be a recurring issue for years to come.

The Realistic Frame

Casgevy represents a genuine medical achievement and, for the patients who have received treatment, transformative individual benefit. It also represents evidence that gene editing medicine is arriving through narrow channels rather than as a broad revolution in disease treatment.

Both truths matter. For patients with severe sickle cell disease who can navigate the access requirements, an effective treatment now exists that did not exist five years ago. For the majority of sickle cell disease patients who cannot access this treatment due to systemic barriers, the technological breakthrough has not yet translated to lived medical benefit.

The trajectory over the next 5-10 years may or may not close this gap. What the first two years have demonstrated is that closing it will require more than just additional approved therapies — it will require systematic attention to the delivery infrastructure that determines whether approvals translate to patient benefit.

Dr. Marcus Wren has no financial relationships with any gene therapy company or pharmaceutical organization mentioned in this article. TimesWriter editorial standards require disclosure of author conflicts of interest.